Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 21 - Drugs for disorders of the muscular or neuromuscular system
Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287)
11/2009
11/11/2009CN100558715C Protein kinase inhibitors
11/11/2009CN100558712C Therapeutic molecules and methods-1
11/11/2009CN100558410C Nucleic acids, polypeptides, and methods for modulating apoptosis
11/10/2009US7615553 E.g., N,N-dimethyl,((5-(hydroxyaminocarbonyl)pyrimidin-2-yl)(piperazin-1,4-ylene)sulfonamide; bioavailability; oral administration; metabolic stability; side effect reduction; psoriasis; anticarcinogenic -proliferative, -arthritic, -inflammatory agent; gene therapy; genetic transcription potentiation
11/10/2009US7615543 Complexes with C-reactive protein (CRP) molecules; rheumatoid arthritis, juvenile chronic (rheumatoid) arthritis, ankylosing spondylitis, psoriatic arthritis, systemic vasculitis, polymyalgia rheumatica, Reiter's disease, Crohn's disease and familial Mediterranean fever
11/10/2009US7615237 Percutaneously absorbable preparations
11/10/2009US7615207 Methods for treating irritable bowel syndrome
11/10/2009CA2457952C Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h) one derivatives for neurodegenerative disorders
11/10/2009CA2378792C Aminothiazole derivatives and their use as crf receptor ligands
11/05/2009WO2009133905A1 Peptide capable of inhibiting activity of human fibroblast growth factor-23 (human fgf-23), and pharmaceutical composition comprising the same
11/05/2009WO2009133861A1 Cyclic amine compound
11/05/2009US20090275751 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof
11/05/2009US20090275537 Certain chemical entities, compositions, and methods
11/05/2009US20090274668 Combined Regulation of Neural Cell Production
11/04/2009EP1542716B1 Growth hormone releasing peptides
11/03/2009US7612238 Such as (R)-2-amino-2-methyl-4-[4-(4,4,5,5,5-pentafluoro-pentyloxy)-phenyl]-butan-1-ol hydrochloride for treatment of disorders or diseases mediated by lymphocytes, and for treating acute or chronic transplant rejection or T-cell-mediated inflammatory or autoimmune diseases
11/03/2009US7612114 Selective estrogen receptor modulator
11/03/2009US7612094 Tri-substituted heteroaryls and methods of making and using the same
11/03/2009US7612033 administering to the cell a composition which comprises the compound to be delivered and an organic halide such as a perfluorocarbon; ultrasound
11/03/2009CA2372668C Novel use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts
10/2009
10/29/2009WO2009131201A1 Therapeutic agent for intermittent claudication
10/29/2009US20090270501 Composition and method for increasing the anabolic state of muscle cells
10/29/2009US20090270469 Substituted oxazolidinones
10/29/2009US20090270452 Use of soluble epoxide hydrolase inhibitors in the treatment of smooth muscle disorders
10/29/2009US20090269281 Calcium/Calmodulin-Dependent Protein Kinase Kinase as a Control Point for Cardiac Hypertrophy
10/28/2009EP2111864A2 Therapeutic methods and uses of sapogenins and their derivatives
10/28/2009EP1503800B1 Treatment and prevention of tissue damage associated with increased c-reactive protein production
10/28/2009EP1379504B1 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
10/28/2009CN101568521A Inhibitors of zinc proteases thioaryl substituted and their use
10/28/2009CN101565419A 7 and 20 dehydro-silybin dialky ether and preparation method and medicine use thereof
10/28/2009CN100554267C Muscle relaxation accelerator and therapeutic agent for muscular tissue diseases such as muscle relaxation failure
10/27/2009US7608701 Corticotropin releasing factor 2 receptor agonists
10/27/2009US7608683 Human leukocyte antigen pan DR-binding peptides for use in the treatment of infections, inflammatory, autoimmune and cancer diseases; has heat shock protein that is capable of binding to MHC class II molecules
10/27/2009US7608638 Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
10/27/2009US7608625 Method for treating bruxism and bruxism-related diseases
10/27/2009US7608610 Transdermal formulation containing androgen, macrocyclic ester or ketone enhancer and thickener; extended time high blood serum concentration; rapidly absorbed gel; treatment of male hypogonadism
10/27/2009US7608609 Pharmaceutical composition
10/27/2009US7608608 Pharmaceutical composition
10/27/2009US7608607 Pharmaceutical composition
10/27/2009US7608606 Transdermal formulation containing androgen, macrocyclic ester or ketone enhancer and thickener; extended time high blood serum concentration; rapidly absorbed gel; treatment of male hypogonadism
10/27/2009US7608605 Transdermal formulation containing androgen, macrocyclic ester or ketone enhancer and thickener; extended time high blood serum concentration; rapidly absorbed gel; treatment of male hypogonadism
10/27/2009US7608452 Polynucleotides encoding cytokine receptor zcytor19
10/27/2009US7608284 Active enamel matrix substance, such as an amelogenin, a processed amelogenin product, or a metabolite can be used in treating conditions in a mammal which present an imbalance in its native immune resposne to external or internal stimuli
10/27/2009US7608245 Transmission and, or amplification of signal ; oral or enteric administering; dissolving; absorption by small inteestines; peptide yy; obesity therapy
10/27/2009CA2493359C Novel polymorph of n-methyl-n-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-.alpha.]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
10/27/2009CA2466724C Benzamide and heteroarylamide as p2x7 receptor antagonists
10/27/2009CA2437006C Aminotriazolopyridine derivatives as adenosine receptor ligands
10/27/2009CA2432713C Aniline derivatives or salts thereof and cytokine production inhibitors containing the same
10/27/2009CA2415966C Tetrahydro-heterocycloazepinyl pyrimidine derivatives
10/27/2009CA2376355C N-heterocyclic derivatives as nos inhibitors
10/22/2009WO2009129501A1 Use of soluble epoxide hydrolase inhibitors in the treatment of smooth muscle disorders
10/22/2009WO2009128558A1 Activator for peroxisome proliferator-activated receptor
10/22/2009WO2009128481A1 Nitrogenated 5-membered heterocyclic compound
10/22/2009US20090264515 Polynucleotide therapy
10/22/2009US20090264506 Delivery of polynucleotide agents to the central nervous system
10/22/2009US20090264466 Certain Chemical Entities, Compositions and Methods
10/22/2009US20090264364 Genes implicated in the regulation of angiogenesis, pharmaceutical preparations containing them and their applications
10/22/2009US20090263783 Nucleic sequence and deduced protein sequence family with human endogenous retroviral motifs, and their uses
10/22/2009US20090263519 Composition and methods for inducing the expression of heat shock proteins
10/22/2009US20090263474 Methods for Treating Autoimmune Diseases in a Subject and In Vitro Diagnostic Assays
10/22/2009US20090263443 Methods for treating post-operative effects such as spasticity and shivering with clondine
10/22/2009US20090263402 Growth Differentiation Factor-11
10/22/2009US20090263367 Composition and method for promoting internal health and external appearance
10/22/2009CA2721339A1 Activating agent for peroxisome proliferator activated receptor
10/21/2009EP2110124A1 Bioavailable Solid Dosage Forms of Metaxalone
10/21/2009EP1492785B9 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
10/21/2009EP1450750B1 Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase
10/21/2009EP1164991B1 Gels formed by the interaction of poly(aldehyde) with various substances
10/21/2009CN101563320A [2-(6-flouro-1H-indol-3-ylsulfanyl)benzyl]methyl amine for the treatment of affective disorders
10/21/2009CN101559198A Medicament for protecting joints and soft tissues
10/20/2009US7605152 such as 16 alpha -fluoro-17 beta -hydroxy-4-methyl-4-aza-5 alpha -androst-1-en-3-one, used for hormone replacement therapy
10/20/2009US7604993 Generation of neuronal cells for use in the treatment of nervous system disorders; preparing nutrient broth contain nerve growth factor, inoculating with cells, producing neuronal precursor cells or glial precursor cells
10/20/2009CA2469821C Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
10/20/2009CA2456127C Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases
10/20/2009CA2393303C Meglumine salt of a specific quinolinecarboxylic acid compound
10/20/2009CA2385130C Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases
10/15/2009WO2009126350A2 Methods and compositions for targeting polyubiquitin
10/15/2009WO2009124693A1 Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of respiratory illness in muscular dystrophy
10/15/2009WO2009054725A3 Means and methods for counteracting muscle disorders
10/15/2009US20090258898 Amides of acetic and propionic acids
10/15/2009US20090258819 Reagents and Methods for Smooth Muscle Therapies
10/15/2009US20090257997 Stable Aqueous Compositions Comprising Bioactive Creatine Species
10/15/2009CA2719440A1 Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of respiratory illness in muscular dystrophy
10/15/2009CA2710398A1 Methods and compositions for targeting polyubiquitin
10/14/2009EP2108367A1 Composition for amelioration/prevention of adverse side effect in steroid therapy
10/14/2009EP2108366A1 Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of respiratory illness in muscular dystrophy
10/14/2009EP1397137B1 Hydantion derivatives as inhibitors of matrix metalloproteinases
10/14/2009EP1356046B1 Cytokine receptor zcytor19
10/14/2009EP1337527B1 Indolylmaleimide derivatives as protein kinase c inhibitors
10/14/2009CN101554451A Ginseng and antler muscle strengthening pills and preparation method thereof
10/14/2009CN100548299C Excitatory amino acid receptor antagonists
10/14/2009CN100548279C Delayed total release gastrointestinal drug delivery system
10/13/2009US7601836 Pyrido[2,3-D]pyrimidine inhibitors of phosphodiesterase (PDE) 7
10/13/2009US7601809 hematopoietic cytokine receptor polypeptide encoded by nucleotides equences for use in the treatment of cancer; restoring normal blood cell levels in patients suffering from anemia, thrombocytopenia, and neutropenia or receiving chemotherapy for cancer; biodrugs
10/13/2009US7601712 Such as (1)-2-(4-chloro-3-((2-chloro-4-(((2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-ly)methoxy)benzoyl)amino)phenyl)-2-methylpropanoic acid; prostaglandin receptor agonists
10/13/2009US7601344 Von Hippel-Lindau (VHL) gene in cancer cells which express neuropeptide Y, neurofilament, and microtubule associated protein 2; plasmids; Parkinson's disease, amyotrophic lateral sclerosis, Huntington's chorea, Alzheimer's disease, brain infarction, spinal cord injury, brain contusion or malignant tumor
10/13/2009US7601337 Delivery of antipsychotics through an inhalation route
10/13/2009CA2455246C Drug preparation comprising .alpha.-lipoic acid, ambroxol and/or inhibitors of the angiotensin-converting enzyme (ace) and its use for the treatment of neurodegenerative diseases
10/13/2009CA2386974C Benzodiazepine derivatives for use in acute or chronic neurological disorders
10/08/2009WO2009123316A1 Heterocyclic derivative and use thereof
1 ... 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 ... 233